A new study finds that under 30% of radiology-focused AI/ML devices authorized by the FDA had clinical testing prior to authorization.
Key Details
- 1FDA has cleared over 1,000 AI/ML devices, most for radiology.
- 2Research published in JAMA Network Open reviewed almost 1,000 algorithms approved from 1995 to June 2024.
- 3Of 723 radiology devices, fewer than 30% underwent any form of clinical testing.
- 4Very few devices were subject to prospective trials before clearance.
- 5Authors highlight a lack of standards for safety and efficacy in FDA authorization of AI/ML devices.
Why It Matters
The rapid proliferation of AI/ML devices in radiology without adequate clinical validation raises concerns about patient safety and efficacy. The findings emphasize an urgent need for more rigorous regulatory oversight and defined testing standards for imaging AI tools.
Source
Radiology Business
Related News
•Radiology Business
AI Model Reduces Need for Gadolinium Contrast in Brain Tumor MRI
UCL researchers develop an AI tool to predict brain tumor MRI enhancement, reducing the need for gadolinium contrast agents.
•Radiology Business
Rad Partners Wins $1.29M FDA Grant for AI Radiology Report Evaluation Study
Cognita Imaging, part of Rad Partners, has received a $1.29M FDA grant to develop a new framework using large language models (LLMs) to evaluate AI-generated radiology reports.
•Radiology Business
Real-World Study: Radiology AI Best in Emergency and Inpatient Settings
A commercial AI tool for intracranial aneurysm detection outperformed in inpatient and emergency settings but yielded limited benefits for outpatients in a major health system study.